MedTrace Logo

Blood Naloxone Levels Following Intradermal Injection in Humans

NCT05876572 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2024-11-01

No results posted yet for this study

Summary

The main purpose of this study is to evaluate pharmacokinetics/pharmacodynamics of intradermal administration of naloxone in healthy adult subjects.

Conditions

Interventions

DRUG

intradermal naloxone

One time 8 mg/0.1 mL dose of naloxone to be administered intradermally

DEVICE

microneedle injection

Intradermal delivery of naloxone using microneedle

Sponsors & Collaborators

Principal Investigators

  • Kathryn Rosenblatt, MD · Johns Hopkins University

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-31
Primary Completion
2024-12-31
Completion
2024-12-31
FDA Drug
Yes

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05876572 on ClinicalTrials.gov